S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia

Neuropsychopharmacology

Volumn 29, Issue 5, 2004, Pages 1004-1011

  Rothermundt, Matthias ^a   Ponath, Gerald ^a   Glaser, Thomas ^b   Hetzel, Guenter ^a   Arolt, Volker ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b BAYER AG   (Germany)

Author keywords

Astrocytes; Longitudinal studies; Neurons; Psychopathology; S100 proteins; Schizophrenia

Indexed keywords

CALCIUM BINDING PROTEIN; PROTEIN S100B;

ADULT; APOPTOSIS; ARTICLE; ASTROCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEGENERATION; DENDRITE; DISEASE EXACERBATION; FEMALE; GLIA CELL; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEGATIVE SYNDROME; NERVE CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; SCHIZOPHRENIA; SYMPTOMATOLOGY; SYNAPSE;

ADULT; ANTIPSYCHOTIC AGENTS; ASTROCYTES; BIOLOGICAL MARKERS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NERVE GROWTH FACTORS; PSYCHIATRIC STATUS RATING SCALES; S100 PROTEINS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 1942420774     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300403     Document Type: Article

References (45)

1. Bartzokis G (2002). Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. Neuropsychopharmacology 27: 672-683.
2. Beaudeux JL, Dequen L, Foglietti MJ (1999). La protéine S-100β: un nouveau marquer biologique de pathologie céré brale. Ann Biol Clin 57: 261-272.
3. DeLisi LE (1999). Defining the course of brain structual change and plasticity in schizophrenia. Psychiatry Res Neuroimaging 92: 1-9.
4. Donato R (2001). S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33: 637-668.
5. Fano G, Biocca S, Fulle S, Mariggio MA, Belia S, Calissano P (1995). The S-100: a protein family in search of a function. Prog Neurobiol 46: 71-82.
6. Gattaz WF, Lara DR, Elkis H, Portel LV, Goncalves CA, Tort AB et al (2000). Decreased S100-beta protein in schizophrenia: preliminary evidence. Schizophr Res 43: 91-95.
7. Gerlai R, Marks A, Roder J (1994). T-maze spontaneous alternation rate is decreased in S100β transgenic mice. Behav Neurosci 108: 100-106.
8. Gerlai R, Roder J (1996). Spatial and nonspatial learning in mice: effects of S100β overexpression and Age. Neurobiol Learn Mem 66: 143-154.
9. Glantz LA, Lewis DA (2000). Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 57: 65-73.
10. Griffin WST, Sheng JG, Mrak RE (1998). Senescence-accelerated overexpression of S100β in brain of SAMP6 mice. Neurobiol Aging 19: 71-76.
11. Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W et al (1998). A follow-up magnetic resonance imaging study of schizophrenia. Arch Gen Psychiatry 55: 145-152.
12. Harrison PJ (1999). The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122: 593-624.
13. Harrison PJ, Eastwood SL (2001). Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia. Hippocampus 11: 508-519.
14. Heizmann CW, Fritz G, Schäfer BW (2002). S100 proteins: structure, functions and pathology. Front Biosci 7: 1356-1368.
15. Henn FA, Braus DF (1999). Structural neuroimaging in schizophrenia. An integrative view of neuromorphology. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4): IV/48-IV/56.
16. Hirsch SR, Kissling W, Bauml J, Power A, O'Connor R (2002). A 28-week comparison of ziprasidone and haloperidole in outpatients with stable schizophrenia. J Clin Psychiatry 63: 516-523.
17. Karson CN, Mrak RE, Schluterman KO, Sturner WQ, Sheng JG, Griffin WST (1999). Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for 'hypofrontality'. Mol Psychiatry 4: 39-45.
18. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
19. Kung L, Conley R, Chute DJ, Smialik J, Roberts RC (1998). Synaptic changes in the striatum of schizophrenic cases: a controlled postmortem ultrastructural study. Synapse 28: 125-139.
20. Lara DR, Gama CS, Belmonte-de-Abreu P, Portela LVC, Goncalves CA, Fonseca M et al (2001). Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatr Res 35: 11-14.
21. Lieberman JA, Sheitman BB, Kinon BJ (1997). Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17: 205-229.
22. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R et al (2003). Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of alonazapine versus haloperidol. Am J Psychiatry 160: 1396-1404.
23. Lindenmayer JP, Bernstein-Hyman R, Grochowski S (1994). Five-factor model of schizophrenia. J Nerv Ment Dis 182: 631-638.
24. Marder SR, Davis JM, Chouinard G (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American Trials. J Clin Psychiatry 58: 538-546.
25. McGlashan TH, Hoffman RE (2000). Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry 57: 637-648.
26. Mimics K, Middleton FA, Lewis DA, Levitt P (2001). Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci 24: 479-486.
27. Pearlson GD, Marsh L (1999). Structural brain imaging in schizophrenia: a selective review. Biol Psychiatry 46: 627-649.
28. Peralta V, Cuesta MJ (1994). Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res 53: 31-40.
29. Peuskens J, Bech P, Möller HJ, Bale R, Fleurot O, Rein W (1999). Amisulpride vs Risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 88: 107-117.
30. Powers RE (1999). The neuropathology of schizophrenia. J Neuropathol Exp Neurol 58: 679-690.
31. Reiber H (2001). Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310: 173-186.
32. Rothermundt M, Missler U, Arolt V, Peters M, Leadbeater J, Wiesmann M et al (2001). Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 6: 445-449.
33. Rothermundt M, Peters M, Prehn JHM, Arolt V (2003). S100B in brain damage and neurodegeneration. Microsc Res Technol 60: 614-632.
34. Rothermundt M, Ponath G, Arolt V (2004). S100B in schizophrenic psychosis. Int Rev Neurobiol 59: 445-470.
35. Schroeter ML, Abdul-Khaliq H, Frühauf S, Höhne R, Schick G, Diefenbacher A et al (2003). Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr Res 62: 231-236.
36. Selemon LD, Goldman-Rakic PS (1999). The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 45: 17-25.
37. Shenton ME, Dickey CC, Frumin M, McCarley RW (2001). A review of MRI findings in schizophrenia. Schizophr Res 49: 1-52.
38. Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E et al (2003). Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 72: 83-87.
39. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S et al (2002). Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71: 877-892.
40. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C et al (1997). Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17: 407-418.
41. Weinberger DR, McClure RK (2002). Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry. Arch Gen Psychiatry 59: 553-558.
42. Whitaker-Azmitia PM, Wingate M, Borella A, Gerlai R, Roder J, Azmitia EC (1997). Transgenic mice overexpressing the neurotrophic factor S-100β show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer's disease and Down's syndrome. Brain Res 776: 51-60.
43. Wiesmann M, Wandinger KP, Missler U, Eckhoff D, Rothermundt M, Arolt V et al (1999). Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psychiatry 45: 1508-1511.
44. Winocur G, Roder J, Lobaugh N (2001). Learning and memory in S100β transgenic mice: an analysis of impaired and preserved function. Neurobiol Learn Mem 75: 230-243.
45. Woods BT (1998). Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am J Psychiatry 155: 1661-1670.